HIGH DOSE DAUNORUBICIN (NSC-83142) IN TREATMENT OF ADVANCED ACUTE MYELOGENOUS LEUKEMIA

被引：0
|
作者：
LIPPMAN, M
ZAGER, R
HENDERSON, ES
机构：
[1] NCI, DIV CANC TREATMENT, LAB HEMATOL, BETHESDA, MD 20014 USA
[2] NCI, DIV CANC TREATMENT, LAB CHEM PHARMACOL, BETHESDA, MD 20014 USA
[3] NCI, DIV CANC TREATMENT, SUPORT CARE BRANCH, BETHESDA, MD 20014 USA
[4] NCI, DIV CANC TREATMENT, CANC THERAPY EVALUATION BRANCH, BETHESDA, MD 20014 USA
来源：
CANCER CHEMOTHERAPY REPORTS PART 1 | 1972年 / 56卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：755 / 760
页数：6
相关论文
共 50 条
  • [31] CHEMOTHERAPY IN ACUTE MYELOGENOUS LEUKEMIA - HIGH-DOSE, HIGHER EXPECTATIONS
    BERMAN, E
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) : 1 - 4
  • [32] HIGH-DOSE RETINOL IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA IN REMISSION
    LIE, SO
    WATHNE, KO
    PETERSEN, LB
    SLORDAHL, SH
    NORUM, KR
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1988, 40 (05) : 460 - 465
  • [33] Outcome analysis of acute myeloid leukemia patients treated with high dose daunorubicin
    Dolatkhah, Roya
    Jam, Effat Irani
    Nikanfar, Alireza
    Esfahani, Ali
    Chavooshi, Sayed Hadi
    Nejati, Babak
    Sanaat, Zohreh
    BIOMEDICAL RESEARCH AND THERAPY, 2019, 6 (09): : 3347 - 3351
  • [34] Salvage treatment for patients with acute myelogenous leukemia treated after intensive induction therapy by daunorubicin.
    Dobashi, N
    Usui, N
    Asai, O
    Yano, S
    Uno, S
    Watanabe, H
    Katori, M
    Yahagi, Y
    Nagamine, M
    Saito, T
    Yamaguchi, Y
    Kasama, K
    Tajima, N
    Yamazaki, H
    Kobayashi, T
    Kuraishi, Y
    BLOOD, 1998, 92 (10) : 209B - 209B
  • [35] Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia (AML).
    Case, DC
    Ebrahim, KS
    Aronson, FR
    Hedlund, JA
    BLOOD, 2000, 96 (11) : 209B - 209B
  • [36] Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C
    Letendre, L
    Noel, P
    Litzow, MR
    Hoagland, HC
    Tefferi, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (02): : 142 - 144
  • [37] DAUNORUBICIN (NSC-82151), VINCRISTINE (NSC-67574), CYTOSINE-ARABINOSIDE (NSC-63878), AND PREDNISONE (NSC-10023) COMBINATION THERAPY FOR ADVANCED ADULT ACUTE-LEUKEMIA
    BURNS, CP
    CANCER CHEMOTHERAPY REPORTS PART 1, 1975, 59 (04): : 757 - 760
  • [38] In vitro cytotoxicity of the LDE:daunorubicin complex in acute myelogenous leukemia blast cells
    Dorlhiac-Llacer, PE
    Marquezini, MV
    Toffoletto, O
    Carneiro, RCG
    Maranhao, RC
    Chamone, DAF
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2001, 34 (10) : 1257 - 1263
  • [39] ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OF TREATMENT BY DAUNORUBICIN
    BERNARD, J
    WEIL, M
    BOIRON, M
    JACQUILLAT, C
    FLANDRIN, G
    GEMON, MF
    BLOOD, 1973, 41 (04) : 489 - 496
  • [40] Infusional etoposide, daunorubicin, vincristine, and cytarabine in relapsed acute myelogenous leukemia.
    Walker, B
    Elkins, S
    Bigelow, C
    Files, J
    JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S289 - S289
12345